Core Insights - Venus Concept Inc. reported financial results for Q2 2025, showing a total revenue of $15.7 million, which is a 5% decrease year-over-year but a 15% increase quarter-over-quarter [5][6] - The company experienced a 20% growth in total systems and subscription sales quarter-over-quarter, with U.S. revenue increasing by 5% year-over-year [3][5] - The company is focusing on cash burn management and strategic initiatives to enhance long-term growth, including the sale of its Venus Hair business for $20 million [3][5] Financial Performance - Total revenue for Q2 2025 was $15.7 million, down from $16.6 million in Q2 2024, with U.S. revenue increasing by $0.4 million to $9.7 million [5][6] - Gross profit decreased by 20% to $9.4 million, with a gross margin of 60.1%, down from 71.5% in the prior year [8] - Operating expenses rose by 6% to $18.5 million, driven by increases in general and administrative and selling and marketing expenses [9] Losses and Adjusted EBITDA - The net loss for Q2 2025 was $11.7 million, or $8.03 per share, compared to a net loss of $20.0 million, or $30.93 per share, in Q2 2024 [11] - Adjusted EBITDA loss for Q2 2025 was $8.8 million, worsening from a loss of $4.1 million in the same quarter last year [11][28] Cash Position and Debt - As of June 30, 2025, the company had cash and cash equivalents of $4.9 million and total debt obligations of approximately $34.3 million, down from $39.7 million at the end of 2024 [12] - The company has made efforts to enhance its balance sheet through various financing transactions, including raising $3.9 million in gross proceeds from equity capital transactions [3][12] Strategic Initiatives - The company announced a definitive agreement to sell its Venus Hair business for $20 million, aiming to focus on its core medical aesthetics business [3][5] - Management emphasized the importance of disciplined cost management and targeted investments to support long-term growth [3]

PLAINVIEW, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, today announced operating results for the three months ended June 30, 2025. "The Company's 2025 second quarter revenue was $20.0 million, slightly down from $20.2 million for the same quarter of the prior year," commented Dr. Jun Ma, President and Chief E ...

Financial Performance - Adjusted EBITDA for Q2 2025 was $133.2 million, representing a 49.8% Adjusted EBITDA margin[8] - Total operating revenues in Q2 2025 reached $267.7 million, a 24% increase compared to $216.6 million in Q1 2025[14] - The company expects Q3 activity to be at similar levels to Q2[28] - The company is comfortable with the 2025 Adjusted EBITDA consensus of approximately $470 million[28] Fleet and Contract Coverage - The company has 22 active rigs out of a fleet of 24 modern rigs[8] - Full year 2025 contract coverage is at 84% with an average dayrate of $145,000, which includes approximately 5.5% coverage related to suspension periods in Mexico[8, 9] - The company added $318 million in backlog revenue year-to-date in 2025[16] - The average day rate for new commitments year-to-date in 2025 is $123,000[16] - The company's 2026 contract coverage is at 47% with an average dayrate of $139,000[20] Liquidity and Balance Sheet - Pro forma liquidity stands at $425 million post July transactions[8] - Debt amortization is $135 million per annum[8]

"Through our AI-powered MarTech and loyalty SaaS platform, we help regulated-market businesses increase customer retention, drive measurable ROI, and grow revenue. Springbig is positioned to remain the premier solution in our industry while creating long-term value for both clients and shareholders," Christopher added. Jason Moos, Springbig's CFO, added "We are reporting year-over-year improvements in both positive Adjusted EBITDA and positive cash flow from operations for the six months ended June 30, 2025 ...

Core Insights - Battalion Oil Corporation reported its financial and operational results for Q2 2025, highlighting a net loss of $3.5 million and an adjusted diluted net loss of $10.6 million [6][9][12]. Operational Highlights - The company completed its 2025 six-well drilling plan ahead of schedule and under budget, with initial production rates from the new wells outperforming legacy wells [2][4]. - The acid gas injection facility treated approximately 2.2 Bcf of gas, but ceased operations on August 11, 2025, leading to a temporary shutdown of part of the Monument Draw field [3][8]. Financial Performance - Average daily net production was 12,989 Boe/d (49% oil), with total operating revenue of $42.8 million, a decrease from $49.1 million in Q2 2024 [4][6]. - The decline in revenue was primarily due to a $5.93 decrease per Boe in average realized prices, partially offset by a 132 Boe/d increase in production [4][6]. - Lease operating and workover expenses increased to $10.98 per Boe, while general and administrative expenses decreased to $2.17 per Boe [5][6]. Liquidity and Balance Sheet - As of June 30, 2025, the company had $219.4 million in term loan indebtedness and total liquidity of $44.6 million [9][15]. - Current assets increased to $83.5 million, with cash and cash equivalents at $44.6 million, up from $19.7 million a year earlier [15][9]. Production and Pricing Data - Crude oil production for Q2 2025 was 584 MBbls, with an average price of $62.14 per Bbl, down from $79.20 in Q2 2024 [20][21]. - Total production volumes for the quarter were 1,182 MBoe, with an average daily production of 12,989 Boe/d [20][21].

Core Viewpoint - Northland Power Inc. reported its financial results for Q2 2025, highlighting significant construction milestones and operational performance despite challenges from below-average wind levels in Europe [2][10]. Financial Performance - Revenue from energy sales in Q2 2025 was $509 million, a decrease of 4% from $529 million in Q2 2024 [8][9]. - Net loss for Q2 2025 was $53 million, compared to a net income of $262 million in Q2 2024 [8][22]. - Adjusted EBITDA for Q2 2025 was $245 million, down 9% from $268 million in Q2 2024 [8][25]. - Free Cash Flow per share was $0.22 in Q2 2025, compared to $0.27 in Q2 2024, reflecting a 15% decrease [8][29]. - Cash provided by operating activities was $451 million in Q2 2025, significantly higher than $171 million in Q2 2024 [8][27]. Project Updates - The Oneida Energy Storage Project, a 250 MW/1.0 GWh facility, commenced commercial operations ahead of schedule and under budget [7]. - The Hai Long Offshore Wind Project achieved first power during the quarter and remains on track for full operations in 2027 [7]. - The Baltic Power Offshore Wind Project is progressing with onshore substation construction and is expected to commence full operations in the second half of 2026 [7]. Operational Highlights - Overall commercial availability was reported at 95% for Q2 2025 [2][12]. - Electricity production from offshore wind facilities decreased by 19% or 174 GWh compared to Q2 2024, primarily due to lower wind resources [12]. - Onshore renewable and energy storage facilities saw a 7% increase in electricity production, attributed to favorable wind conditions in New York and Canada [14]. Guidance Update - The company revised its full-year financial guidance for Adjusted EBITDA to a range of $1.2 billion to $1.3 billion, down from the previous range of $1.3 billion to $1.4 billion [34]. - Free Cash Flow per share guidance was adjusted to between $1.15 and $1.35, compared to the earlier projection of $1.30 to $1.50 [34].

Financial Data and Key Metrics Changes - The company reported a revenue of $120 million for Q2 2025, reflecting a year-over-year growth of over 20% [5] - Adjusted EBITDA loss improved to $4.1 million in Q2 2025, a $4.6 million improvement compared to the same quarter last year [6][20] - Consolidated revenue increased by 21.5% to $119.8 million compared to Q2 2024 [15] - Gross profit for the quarter was $17.5 million, a 34% increase year-over-year, with a gross margin of 14.6% [16][17] Business Line Data and Key Metrics Changes - Patient services revenue was $55.9 million, a 7% increase year-over-year, representing 47% of total revenue [16] - Pharmacy revenue reached $62.6 million, up 41% year-over-year, now constituting 52% of total revenue [16] - The pharmacy business is forecasted to grow over 35% for the full year compared to the previous year [9] Market Data and Key Metrics Changes - The company added over 50,000 capitated lives in Nevada and California through new contracts effective in Q2 [6] - An expanded capitation relationship in Nevada added 49,000 Medicaid patients, and a verbal agreement in Florida will add over 40,000 Medicare Advantage lives [7][8] Company Strategy and Development Direction - The company aims to achieve positive adjusted EBITDA in Q4 2025, driven by strong growth in pharmacy and fee-for-service businesses [6][26] - The focus is on expanding capitated partnerships and leveraging technology to enhance operational efficiency [12][26] - The company is launching three AI enablement efforts in Q3 to improve performance and cost management [13][24] Management's Comments on Operating Environment and Future Outlook - Management noted that drug cost trends are increasing, but the company is positioned to provide value to payer partners through effective cost management [44][45] - The company expects to recognize revenue from new contracts in Q4 2025, with substantial growth anticipated in Florida [47][56] - Management expressed confidence in achieving the high end of the revenue guidance for 2025, projecting $460 million to $480 million [22] Other Important Information - The company announced the retirement of its current Chairman, Richard Barish, and the election of Anne McGeorge as the new Chair [13][14] - The company is focused on improving drug margins through strategic purchasing and active formulary management [21] Q&A Session Summary Question: Can you talk about the dispensing gross margin? - The increase in gross margin is attributed to improved drug procurement and scale, with significant growth year-over-year [28][30] Question: Thoughts on drug pricing reform impacts? - Management believes the Inflation Reduction Act will be net positive for the company, benefiting both capitated and fee-for-service margins [32][33] Question: Any specific drugs impacting EBITDA? - No significant risks were identified in the current drug portfolio that would impact EBITDA negatively [36] Question: Pressure on gross patient service margin? - The pressure is primarily from capitation margins, with expectations for improvement as new contracts mature [37][39] Question: Observations on oncology spend trends? - The company noted a stable medical loss ratio despite rising drug costs, indicating effective cost management [44][45] Question: Details on new patient contracts? - The company expects substantial growth in patient lives, particularly in Florida, with projections of around 100,000 Medicare Advantage lives by year-end [57][58] Question: Clarification on fully delegated risk arrangements? - The company clarified that it takes risk for Part B oncology services and has authority over utilization management and network design [61][62]

Core Insights - Bird Construction is executing its 2025-2027 Strategic Plan, focusing on sectors with long-term demand drivers and maintaining a risk-balanced work program to drive growth and margin accretion [1] - The company has a record backlog of $4.6 billion, which positions it well to capitalize on future opportunities once market uncertainties resolve [1][2] Financial Performance - In Q2 2025, Bird's construction revenue was $850.8 million, a decrease of 2.6% from $873.5 million in Q2 2024 [5][7] - Net income for Q2 2025 was $20.3 million, down from $21.4 million in Q2 2024, while adjusted earnings increased by 18% to $27.6 million [5][6] - Adjusted EBITDA for Q2 2025 was $54.9 million, representing a margin of 6.5%, up from 5.3% in the prior year [5][8] Backlog and Securements - Bird secured almost $1.2 billion in additional work in Q2 2025, increasing its backlog to a record $4.6 billion [2][8] - Year-to-date securements totaled $2.5 billion, nearly $1.0 billion higher than the previous year [8] Operational Highlights - The company generated strong operational cash flow of $54.5 million in Q2 2025, a 14.8% increase from the same quarter in 2024 [8] - Bird's liquidity position remains robust, with $142.6 million in cash and an additional $231.7 million available under its credit facility [8] Project Awards - In Q2 2025, Bird was awarded five projects valued at over $650 million, including significant contracts in infrastructure and industrial sectors [8][14]

Q2 2025 Financial Results August 13, 2025 2 © 2025 Forian Inc. All Rights Reserved. Revenue and Adjusted EBITDA | | | | ($000's) Three Months Ended June 30, | | | | | ($000's) Six Months Ended June 30, | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | Period-over- | | | | Period-over | | | | 2025 | | 2024 | | Period % | 2025 | | 2024 | Period % | | | | Unaudited | | Unaudited | | Change | Unaudited | | Unaudited | Change | | | Revenue | $ | 7,476 | $ | 4,777 | 56% | $ | 1 ...

Core Viewpoint - Motorsport Games Inc. reported significant growth in its second quarter of 2025, with record player activity and increased revenues driven by the success of the Le Mans Ultimate game and its marketing efforts [2][3]. Financial Highlights - Consolidated revenue for Q2 2025 was approximately $2.6 million, a 37.7% increase from approximately $1.9 million in Q2 2024 [3]. - Gross profit rose to $2.1 million, up from $1.1 million year-over-year, with a gross profit margin increase to 82.4% from 59.0% [3]. - Net income for Q2 2025 was $4.2 million, an improvement of 103.0% compared to $2.1 million in Q2 2024, with net income per share for Class A common stock at $0.82, up from $0.77 [4][10]. - Adjusted EBITDA for Q2 2025 was $3.7 million, a significant improvement from an Adjusted EBITDA loss of $0.5 million in the same period last year [5]. Operational Developments - The company released Le Mans Ultimate Version 1.0 on July 22, 2025, featuring new cars and advanced game mechanics [10]. - The expansion downloadable content for Le Mans Ultimate, including the European Le Mans Series, is expected to be delivered by the end of Q3 2025 [2]. Cash Flow and Liquidity - As of June 30, 2025, the company had cash and cash equivalents of approximately $2.4 million, which increased to $2.8 million by July 31, 2025 [11]. - The company generated an average positive cash flow from operations of approximately $46,000 per month during the first half of 2025, primarily due to settlements with Wesco Insurance Company and HC2 Holdings [11]. Future Outlook - The company is focused on further growing the Le Mans franchise and exploring new titles to diversify its income streams [2]. - Future liquidity and capital requirements will support ongoing operations, product development, and capital expenditures [12].